|
WO03017999A1
|
|
Treatment of scleroderma
|
|
AU2002356130A1
|
|
Treatment for lupus erythematosus
|
|
AU4064402A
|
|
Method for identifying compounds for inhibition of neoplastic lesions
|
|
WO02067936A1
|
|
Methods for treatment of inflammatory bowel disease
|
|
US6472420B2
|
|
Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
|
|
AU3241302A
|
|
Method for treating neoplasia by administering an anti-her2 antibody and a cgmp-specific phosphodiesterase inhibitor
|
|
US6465494B1
|
|
Methods for treatment of cystic fibrosis
|
|
US6479493B1
|
|
Methods for treatment of type I diabetes
|
|
US6486158B1
|
|
[4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia
|
|
US6380206B1
|
|
Method of inhibiting neoplastic cells with 4,5-diaminopyrimidine derivatives
|
|
US6369092B1
|
|
Method for treating neoplasia by exposure to substituted benzimidazole derivatives
|
|
AU5532201A
|
|
Method for treating a patient with neoplasia by treatment with a topoisomerase iinhibitor
|
|
US6455703B2
|
|
1,3,6,-Trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia
|
|
US6420410B1
|
|
Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
|
|
US6569638B1
|
|
Method for screening compounds for the treatment of neoplasia
|
|
US6555547B1
|
|
Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
|
|
WO0044372A1
|
|
A method for treating patients with acne by administering a cyclic gmp pde inhibitor
|
|
AU1833000A
|
|
Method for diagnosing neoplasia
|
|
US6358992B1
|
|
Method of inhibiting neoplastic cells with indole derivatives
|
|
AU5953899A
|
|
Method for identifying compounds for inhibition of neoplastic lesions
|
